İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2023

Diffuse alveolar haemorrhage in children: an international multicentre study

ERJ Open Research

YÖKSİS OpenAlex Açık erişim · gold SJR Q1 JCR Q1 Atıf 24 Üst %10 Yüzdelik 94.3% FWCI 3.73
Yıl
2023
ISSN
2312-0541
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Background: Paediatric diffuse alveolar haemorrhage (DAH) is a rare heterogeneous condition with limited knowledge on clinical presentation, treatment and outcome. Methods: A retrospective, descriptive multicentre follow-up study initiated from the European network for translational research in children's and adult interstitial lung disease (Cost Action CA16125) and chILD-EU CRC (the European Research Collaboration for Children's Interstitial Lung Disease). Inclusion criteria were DAH of any cause diagnosed before the age of 18 years. Results: Data of 124 patients from 26 centres (15 counties) were submitted, of whom 117 patients fulfilled the inclusion criteria. Diagnoses were idiopathic pulmonary haemosiderosis (n=35), DAH associated with autoimmune features (n=20), systemic and collagen disorders (n=18), immuno-allergic conditions (n=10), other childhood interstitial lung diseases (chILD) (n=5), autoinflammatory diseases (n=3), DAH secondary to other conditions (n=21) and nonspecified DAH (n=5). Median (IQR) age at onset was 5 (2.0-12.9) years. Most frequent clinical presentations were anaemia (87%), haemoptysis (42%), dyspnoea (35%) and cough (32%). Respiratory symptoms were absent in 23%. The most frequent medical treatment was systemic corticosteroids (93%), hydroxychloroquine (35%) and azathioprine (27%). Overall mortality was 13%. Long-term data demonstrated persistent abnormal radiology and a limited improvement in lung function. Conclusions: Paediatric DAH is highly heterogeneous regarding underlying causes and clinical presentation. The high mortality rate and number of patients with ongoing treatment years after onset of disease underline that DAH is a severe and often chronic condition. This large international study paves the way for further prospective clinical trials that will in the long term allow evidence-based treatment and follow-up recommendations to be determined.

Konular

  • Vasculitis and related conditions
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Hemophilia Treatment and Research

Birincil konu Vasculitis and related conditions

Yazarlar

  1. Astrid Mansen Ring
  2. Nicolaus Schwerk
  3. EMİNE NURAL KİPER
  4. AYŞE TANA ASLAN
  5. Paul Aurora
  6. Roser Ayats
  7. Ines Azevedo
  8. Teresa Bandeira
  9. Julia Carlens
  10. Silvia Castillo-Corullon
  11. FATMA NAZAN ÇOBANOĞLU ANKARA ÜNİVERSİTESİ
  12. Basil Elnazir
  13. NAGEHAN EMİRALİOĞLU ORDUKAYA
  14. TUĞBA ŞİŞMANLAR EYÜBOĞLU
  15. Michael Fayon
  16. TUĞBA RAMASLI GÜRSOY
  17. Claire Hogg
  18. Karsten Kötz
  19. BÜLENT TANER KARADAĞ
  20. Vendula Látalová
  21. Katarzyna Krenke
  22. Joanna Lange
  23. Effrosyni Manali
  24. Borja Osona
  25. Spyros Papiris
  26. Marijke Proesmann
  27. Philippe Reix
  28. Lea Roditis
  29. Sune Rubak
  30. Nisreen Rumman
  31. Deborah Snijders
  32. Florian Stehling
  33. Laurence Weiss
  34. ELMAS EBRU YALÇIN HACETTEPE ÜNİVERSİTESİ
  35. FAZILCAN ZİREK ANKARA ÜNİVERSİTESİ
  36. Andrew Bush
  37. Annick Clement
  38. Matthias Griese
  39. Frederik Fouirnaies Buchvald
  40. Nadia Nathan
  41. Kim Gjerum Nielsen